Literature DB >> 19953253

Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease.

Agostina Siniscalchi, Teresa Dentamaro, Alessio Perrotti, Paola Tatangelo, Paolo de Fabritiis, Tommaso Caravita.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19953253     DOI： 10.1007/s00277-009-0867-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  2 in total

1.  Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients.

Authors:  Shenghao Wu; Cuiping Zheng; Songyan Chen; Xiaoping Cai; Yuejian Shi; Bijing Lin; Yuemiao Chen
Journal:  Biomed Res Int       Date:  2015-09-06       Impact factor: 3.411

2.  Long-term reversibility of renal dysfunction associated to light chain deposition disease with bortezomib and dexamethasone and high dose therapy and autologous stem cell transplantation.

Authors:  Tomás J González-López; Lourdes Vázquez; Teresa Flores; Jesus Fernando San Miguel; Ramon García-Sanz
Journal:  Clin Pract       Date:  2011-11-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.